Amazon is stepping into the pharmaceutical industry by launching an exclusive line of over-the-counter health products.
Some analysts say this could benefit customers by causing a price war. and forcing CVS and other pharmacies to lower prices.
There's a new item coming to Chipotle menus: the fast casual chain is introducing quinoa as an alternative to its lime cilantro rice. It's prepared with some lime, citrus juice, cumin, and fresh cilantro. Chipotle's founder Steve Ells says the chain is considering adding salads with other kinds of grains, in addition to nachos and quesadillas.
There's a new medal event at the Olympics: Tinder.
The dating app is releasing data on the most-swiped athletes at the Pyeongchang games. Male bobsledders and female snowboarders are taking home the gold. Male hockey players, skiers, and skeleton racers also placed high. So did female lugers. Tinder's been a mainstay of the Olympic Village since the 2014 games in Sochi. The platform says its seen a 348 percent spike in usage at the games this year. Olympians have free access to Tinder's gold tier.
We spoke with a farmer about how tariffs, trade policy, drought, and packer consolidation are reshaping the economics of American ranching and farming.
John Serafini, CEO of Hawkeye 360, breaks down the company’s 87% revenue growth, global demand for space-based intelligence and plans to scale its business.
Dan Niles, Founder and Portfolio Manager at Niles Investment Management, breaks down NVIDIA’s blowout earnings, 70% growth forecast and AI spending boom.
Edwin Cywinski, CEO of SunScout Holding Limited, explains how solar-powered robotic mowers are transforming lawn care and the company’s plans to scale.
Nathan Bomey, Business Reporter at Axios and author of The Axios Closer newsletter, explains why Wall Street is turning NVIDIA’s AI chips into financial assets.
Jamie Siminoff, Founder and Chief Inventor of Ring, explains the company’s new TAKE encryption standard and its push to put privacy and video data control first
Xavier Martinez, News Associate at The Wall Street Journal, breaks down Moderna’s mRNA ambitions, its pipeline beyond COVID-19 and the challenges ahead.